Skip to player
Skip to main content
Search
Upload
For you
Explore
Following
Log in
Company
About
Press
Jobs
Dailymotion Pro
Support
Developers
Advertisers
Accessibility
Help Center
Legal
Manage Cookies
Privacy and Cookie Policy
Legal notices
Terms
All videos
© 2026 Dailymotion
Watch fullscreen
Add to Playlist
Report
Benzinga
Follow
Minerva Stock Rises After Securing $200M for Schizophrenia Drug Trial
1 year ago
Minerva Neurosciences secured up to $200M in funding to advance its schizophrenia drug roluperidone. The financing follows FDA approval of its Phase 3 trial plan, aiming to treat negative symptoms unmet by current therapies.
Category
🗞
News
Show less
Recommended
8:42
Protesters Shut Down Vote on Google's 500 MW Minnesota Data Center
Land4DataCenter
1:05
Cannabis Funding Opens
Benzinga
0:47
Cancer Drug Breakthrough
Benzinga
New
0:47
6.3 Million Americans Could Lose Food Stamps
Cheddar News
New
0:40
Americans Drowning in Record $1.29 Trillion Credit Card Debt
Cheddar News
New
3:05
Stock Market Today: Nvidia Rout Sinks Nasdaq, S&P 500 Futures as Board Weighs Jensen Huang’s Future — CRWV, TTEK, FNV in Focus
Benzinga
New
0:56
Children's Place Files Chapter 11
Benzinga
New
0:56
California Rejects Wealth Tax
Benzinga
7:56
Cognition Therapeutics Is Targeting A Critical Form Of Dementia
Benzinga
10:41
Novel Therapy Shows Promising Results In On-Going Trials, Receives 3 Orphan Drug Designations From The FDA
Benzinga
2:14
Notorious Pharma Bro Martin Shkreli
Bullish Studio
6:19
Ending the Orphan Disease Crisis: A Nano-Revolution in Medicine
Money Explainers
17:39
Clinical Trial Results Show Positive Signs For Potential New Dementia Treatment
Benzinga
1:27
FDA Greenlights First Novel ADHD Medication in Over 20 Years --- Simtriyo
Buzzline
0:49
Regeneron Trump Admin Deal
Benzinga
0:40
FDA Approves First Novel Schizophrenia Drug in 70 Years, Impacting Up to 3 Million Patients in the US
Benzinga
New
0:33
Gas Prices Finally Drop Below $4
Cheddar News
8:50
Meta Revealed Behind $15B Kentucky Data Center as Residents Sue
Land4DataCenter
New
1:02
Nvidia Shares Extend Losses
Benzinga
New
1:01
Mars Expands US Manufacturing
Benzinga
11:43
Small Changes… Big Effects! Breakthrough Therapies Are The Name Of The Game For This Biopharma
Benzinga
11:39
2025 Is Shaping Up To Be A Big Year For This Drug Maker Working To Cure Dementia
Benzinga
2:03
People with schizophrenia struggling to find medication amid nationwide quetiapine shortage
ABC NEWS (Australia)
8:32
Candel Therapeutics (NASDAQ: $CADL): Revolutionizing Glioma Treatment and Redefining Hope
Benzinga
16:00
This Biotech Just Cleared A Big FDA Hurdle In Its Quest To Improve ADHD Treatment
Benzinga